Minerva Neurosciences | NERV - SCHULD





SCHULD Veränderung Datum
Acadia Pharmaceuticals USD 52.19M 2.62M 2025-12
Adma Biologics USD 204.41M 121.28M 2026-03
ALKERMES USD 1.58B 1.51B 2026-03
Alterity Therapeutics Limited AUD 210.39K 120.67K 2023-06
AstraZeneca USD 33.92B 4.3B 2026-03
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Cipla INR 4.38B 231.9M 2025-03
Clal Biotechnology ILS 35.76M 28.27M 2023-12
Compugen USD 2.93M 14K 2026-03
CSL USD 11.96B 219M 2024-12
Eli Lilly USD 42.5B 3.6M 2025-12
Esperion Therapeutics USD 262.92M 1.76M 2024-09
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Grifols EUR 9.23B 626.05M 2024-12
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
J&J USD 47.93B 2.14B 2025-12
Merck USD 49.34B 7.97B 2025-12
Minerva Neurosciences USD 0 0 2024-09
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 47B 11.62B 2026-03
Novavax USD 233.31M 4.23M 2024-09
Pfizer USD 63.73B 231M 2026-03
Roche Holding CHF 33.03B 1.41B 2025-06
Sanofi EUR 20.33B 1.43B 2025-12
Takeda JPY 4.85T 208B 2025-12
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12